For Immediate Release
Chicago, IL – December 12, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Myriad Genetics Inc. (MYGN), Sanofi (SNY), Abbott Laboratories (ABT), Johnson & Johnson (JNJ) and AstraZeneca (AZN).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
Myriad Teams Up with Sanofi
Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently collaborated with global pharmaceutical products maker Sanofi (SNY) and Population Health Research Institute (“PHRI”) at Hamilton Health Sciences and McMaster University. This association comes as a major breakthrough for Myriad, which is currently aiming to establish itself as a strong player in the companion diagnostic market.
As per the agreement, Myriad RBM will analyze more than 8,000 serum samples from pre and early diabetic patients to conduct the protein biomarker research for the ORIGIN (Outcome Reduction with Initial Glargine Intervention) study. The company expects to conduct the research with its DiscoveryMAP 250+ quantitative immunoassay panel.
Funded by Sanofi and analyzed and managed by PHRI, ORIGIN is the world’s longest and largest randomized clinical trial in pre- and early diabetes. Covering over 40 countries worldwide, this cardiovascular outcomes trial evaluated Lantus (insulin glargine) versus standard care in over 12,500 patients at high cardiovascular risk with pre-diabetes or early type 2 diabetes mellitus. Both Myriad and Sanofi are optimistic about the protein biomarker research for ORIGIN study using Myriad RBM's technology, which they expect will identify the biomarker profiles that might improve treatment and patient care.
Myriad expects this new alliance to add up to $10 million in its companion diagnostic service revenue over the next two fiscal years. Myriad stated that the agreement was presumed in the company’s earlier provided companion diagnostic outlook for fiscal 2013 ($25–$28 million).
Myriad is conducting multiple studies in various areas in the companion diagnostic market. Over the recent past, the company has entered into several agreements that would further strengthen its foothold in this growing market. Apart from Sanofi, it has agreements with several pharmaceutical majors including Abbott Laboratories (ABT), Johnson & Johnson (JNJ) and AstraZeneca (AZN).
Moreover, RBM is expected to place Myriad as a leader in this arena based on the former’s proprietary protein technology and its 550 immunoassays. These developments should augur well for the long-term development of the company. The stock retains a Zacks #1 Rank (Strong Buy in the short term).
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com